西安国际医学投资股份有限公司 外部信息报送和使用管理制度 （第十三届董事会第五次会议修订通过） 第一章 总则 第二章 外部信息报送和使用 第四条 公司控股股东、持股 5%以上股东、董事、监事和高级管 理人员，以及因职务或业务关系获取信息的人员（以下统称"其他相 关涉密人员"）应当遵守信息披露内控制度的要求，对公司定期报告 及重大事项履行必要的传递、审核和披露流程。 第五条 公司控股股东、持股 5%以上股东及其关联方、董事、监 事和高级管理人员及其他相关涉密人员在定期报告编制、公司重大事 项筹划期间，负有保密义务。定期报告、临时报告公布前，不得以任 1 何形式、任何途径向外界或特定人员泄漏定期报告、临时报告的内容， 包括但不限于业绩座谈会、分析师会议、接受投资者调研座谈等方式。 第六条 对于无法律法规依据的外部单位年度统计报表等报送要 求，公司应拒绝报送。 第七条 公司依据法律法规的要求应当报送的，公司董事会秘书 负责将报送的外部单位相关人员作为内幕知情人登记在案备查。 第一条 为加强西安国际医学投资股份有限公司（以下简称"公 司"）定期报告及重大事项在编制、审议和披露期间，公司外部信息 报送和使用管理，依据《 ...

董事会对独立董事独立性自查情况的专项意见 董 事 会 二○二五年四月二十三日 西安国际医学投资股份有限公司 西安国际医学投资股份有限公司（以下简称"公司"）董事会根 据中国证券监督管理委员会《上市公司独立董事管理办法》、深圳证 券交易所《上市公司自律监管指引第1号——主板上市公司规范运作》 等有关要求，就公司现任独立董事师萍女士、张宝通先生、李成先生 独立性情况进行评估并出具如下专项意见： 经核查独立董事师萍女士、张宝通先生、李成先生的任职经历以 及签署的相关自查文件，上述人员未在公司担任除独立董事以外的任 何职务，也未在公司主要股东公司担任任何职务，与公司以及主要股 东之间不存在利害关系或其他可能妨碍其进行独立客观判断的关系， 不存在其他影响独立董事独立性的情况，符合中国证券监督管理委员 会《上市公司独立董事管理办法》、深圳证券交易所《上市公司自律 监管指引第 1 号——主板上市公司规范运作》等相关规则中对独立董 事独立性的相关要求。 西安国际医学投资股份有限公司 ...

作为西安国际医学投资股份有限公司（以下简称"公司"）的独立董 事，2024 年度，本人严格按照《中华人民共和国公司法》、中国证监会《上 市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 1 号 ——主板上市公司规范运作》《公司章程》以及《独立董事工作细则》等 相关法律法规、制度的规定和要求，以勤勉尽责的态度履行独立董事的职 责，通过审阅公司报送的资料、加强与公司审计机构的沟通以及亲自进行 调研等多种方式了解公司经营情况；积极参加公司董事会和股东大会，认 真审议各项议案，充分发挥专业特长并发表独立意见，在董事会规范运作 和重大决策的酝酿等方面做出大量工作，为董事会科学决策起到积极作用， 切实维护了公司和广大股东的利益。现将 2024 年度履职情况报告如下： 一、独立董事基本情况 （一）个人工作履历、专业背景以及兼职情况 李成，男，中共党员，经济学博士，西安交通大学二级教授，博士生 博导。曾任陕西财经学院金融系主任，西安交通大学金融系主任；全国金 融专业研究生教育指导委员会委员，国家教育部金融专业教学指导委员会 委员，中国国际金融学会学术委员会委员、常务理事，陕西省三秦学者， 西安市人民政府参事，西 ...

数据四舍五入，查看更多财务数据>> 一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.1100 | -0.1600 | 31.25 | -0.5200 | | 每股净资产（元） | 1.63 | 1.73 | -5.78 | 1.87 | | 每股公积金(元) | 0.47 | 0.46 | 2.17 | 0.48 | | 每股未分配利润(元) | 0.0088 | 0.12 | -92.67 | 0.28 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 48.15 | 46.18 | 4.27 | 27.11 | | 净利润(亿元) | -2.54 | -3.68 | 30.98 | -11.77 | | 净资产收益率(%) | -6.76 | -9.03 | 25.14 | -24.36 | 二、前10名无限售条件股东持股情况 三、分红送配方案情况 不分配不转增 | 名称 | 持有数 ...

Financial Performance - The company's operating revenue for 2024 was CNY 4,815,466,752.34, representing a 4.28% increase from CNY 4,617,873,479.43 in 2023[20] - The net profit attributable to shareholders for 2024 was a loss of CNY 254,128,508.13, an improvement of 31.01% compared to a loss of CNY 368,360,645.24 in 2023[20] - The net cash flow from operating activities decreased by 7.19% to CNY 1,009,119,813.21 from CNY 1,087,334,386.41 in the previous year[20] - The total assets at the end of 2024 were CNY 10,636,321,992.89, down 6.05% from CNY 11,321,135,811.77 at the end of 2023[20] - The net assets attributable to shareholders decreased by 5.96% to CNY 3,674,927,755.19 from CNY 3,908,017,195.19 in 2023[20] - The basic earnings per share improved to -CNY 0.11 from -CNY 0.16 in 2023, reflecting a 31.25% increase[20] - The weighted average return on equity improved to -6.76% from -9.03% in the previous year, indicating a positive trend[20] Strategic Development - The company has undergone a strategic transformation focusing on healthcare services and modern medical technology applications since 2018[19] - The company is positioned to benefit from the ongoing healthcare reforms and increasing demand for high-quality medical services in China[34] - The company aims to enhance its core competitiveness through a "comprehensive medical + specialty" model, focusing on the integration of online and offline services[144] - The company plans to improve its medical service system through institutional innovation, management reform, and technological updates by 2025[145] - The company aims to enhance patient experience by implementing a full-cycle service upgrade plan and integrating online and offline services[153] Healthcare Market Insights - The average healthcare expenditure per capita in 2024 was ¥2,547, a 3.6% increase from the previous year, indicating rising healthcare demand[32] - The elderly population (60 years and above) in China reached 31,031 million in 2024, accounting for 22% of the total population, highlighting the growing market for healthcare services[32] - The silver economy market in China is estimated to be around ¥7 trillion, representing 6% of the GDP, with significant growth potential projected for the coming decades[33] - The healthcare industry in China is expected to grow significantly due to an aging population (14.8% aged 65 and above) and a high prevalence of chronic diseases (over 300 million patients)[142] Operational Highlights - The company operates two major hospitals: Xi'an High-tech Hospital and Xi'an International Medical Center Hospital, with a focus on comprehensive medical services and specialized departments[38] - The company has established a high-level medical health service platform covering the entire life cycle, with a growing influence in the healthcare industry[39] - The company provided outpatient services totaling 2.5727 million visits, a year-on-year increase of 7.70%, and inpatient services of 205,700 visits, a year-on-year increase of 10.73%[42] - The company has successfully implemented a "comprehensive medical + specialty" business model, addressing diverse healthcare needs and enhancing service quality[40] Research and Development - The company approved 54 national and provincial-level research projects, published 122 SCI papers, and authorized 58 patents during the year[63] - The hospital published 66 academic papers in 2024, including 22 SCI papers and 18 core journal papers, and was granted 2 patents[72] - The hospital achieved a breakthrough in research with 48 projects approved, including 1 national natural science fund project, marking a new level of research strength[87] Governance and Management - The company adheres to legal regulations and continuously improves its corporate governance structure, ensuring compliance with relevant laws and regulations[183] - The company maintains independence from its controlling shareholder in business operations, personnel, assets, and finances[183] - The board consists of 9 members, including 3 independent directors, ensuring compliance with legal requirements[184] - The company emphasizes transparency in information disclosure, ensuring all shareholders have equal access to information[186] Future Plans - The company plans to enhance its core competitiveness by accelerating the construction of new medical projects and improving overall medical service and health management levels[178] - The company aims to establish a "data-driven, process-controlled" evaluation management system by 2025, focusing on enhancing data quality control and ensuring accurate multi-platform data reporting[159] - The company will explore the application of large model technology in medical quality management and cost control, aiming for real-time error correction in quality control processes[162]

Financial Performance - The company's operating revenue for Q1 2025 was ¥997,091,245.37, a decrease of 14.99% compared to ¥1,172,923,244.52 in the same period last year[5]. - The net loss attributable to shareholders was ¥106,353,858.88, slightly worsening by 1.37% from a loss of ¥104,912,277.28 in the previous year[5]. - Total operating revenue for the current period was ¥997,091,245.37, a decrease of approximately 15% from ¥1,172,923,244.52 in the previous period[17]. - Net loss for the current period was ¥132,959,986.79, compared to a net loss of ¥131,877,100.92 in the previous period, indicating a slight increase in losses[18]. - Total comprehensive income for the period was -132,959,986.79, compared to -131,877,100.92 in the previous period, indicating a slight increase in losses[19]. - Basic and diluted earnings per share were both -0.0471, slightly worse than -0.0464 in the previous period[19]. Cash Flow - The net cash flow from operating activities increased by 11.20% to ¥243,804,159.36, compared to ¥219,246,919.94 in the same period last year[5]. - Net cash flow from operating activities was 243,804,159.36, an increase from 219,246,919.94 in the previous period[21]. - Cash inflow from operating activities totaled 1,076,605,731.63, down from 1,221,898,669.41 in the previous period[20]. - Cash outflow from operating activities was 832,801,572.27, compared to 1,002,651,749.47 in the previous period[21]. - Net cash flow from investing activities was -71,687,778.63, an improvement from -137,436,233.21 in the previous period[21]. - Cash inflow from financing activities was 99,980,000.00, down from 199,400,000.00 in the previous period[21]. - Net cash flow from financing activities was -351,075,002.20, worsening from -283,609,925.44 in the previous period[21]. - The ending cash and cash equivalents balance was 369,603,381.91, down from 742,163,400.11 in the previous period[21]. Assets and Liabilities - The total assets at the end of the reporting period were ¥10,318,842,882.85, down 2.98% from ¥10,636,321,992.89 at the end of the previous year[5]. - Total assets decreased to ¥10,318,842,882.85 from ¥10,636,321,992.89, a reduction of approximately 3%[15]. - Current liabilities totaled ¥4,075,263,256.04, down from ¥4,151,485,482.84, representing a decrease of about 2%[15]. - Non-current liabilities decreased to ¥2,904,549,572.58 from ¥3,012,846,469.03, a decline of approximately 4%[15]. - The company's total equity decreased to ¥3,339,030,054.23 from ¥3,471,990,041.02, indicating a decline of approximately 4%[15]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 109,907, with the largest shareholder holding 27.25% of the shares[10]. Other Information - Non-recurring gains and losses amounted to ¥13,392,880.03, primarily from government subsidies and fair value changes of financial assets[6]. - The company reported a significant reduction in credit impairment losses by 423.78% compared to the previous year, indicating improved asset quality[8]. - The company has not disclosed any new product developments or market expansion strategies in this report[5]. - The company's weighted average return on equity was -2.94%, a decrease of 0.22% from -2.72% in the previous year[5]. - The company's cash and cash equivalents decreased to ¥471,603,381.91 from ¥590,562,003.38, a drop of about 20%[13]. - Accounts receivable decreased to ¥690,857,166.93 from ¥739,394,118.00, reflecting a decline of approximately 7%[13]. - Inventory decreased to ¥63,274,718.58 from ¥81,005,105.26, a reduction of about 22%[14]. - The company’s first quarter report was not audited[23].

Company Overview - International Medical's closing price on April 17 was 5.3 yuan, an increase of 1.53%, with a latest price-to-book ratio of 3.28 and a total market capitalization of 11.98 billion yuan [1] - As of September 30, 2024, the number of shareholders reached 107,360, an increase of 3,652 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company specializes in health care services and the application of modern medical technology, with main products including medical services, software, and information technology services [1] Performance Metrics - For the third quarter of 2024, the company reported revenue of 3.606 billion yuan, a year-on-year increase of 7.85%, while net profit was -212.11 million yuan, a year-on-year decrease of 4.59%, with a gross profit margin of 9.19% [1] - The company's price-to-earnings (P/E) ratio (TTM) is -33.45, and the static P/E ratio is -32.52, with a price-to-book ratio of 3.28 [2] - The industry average P/E ratio is 45.40 (TTM) and 42.22 (static), with an average market capitalization of 14.162 billion yuan [2] Industry Comparison - The median P/E ratio in the industry is 47.48 (TTM) and 35.52 (static), with a median market capitalization of 4.862 billion yuan [2] - Other companies in the industry, such as Puri Eye Hospital and He’s Eye Hospital, have significantly higher negative P/E ratios, indicating potential challenges in profitability compared to International Medical [2]

海凭集团董事长宋广征介绍中国医疗器械产业发展趋势与合作机遇。他表示，海凭集团济南园是集团事 业发展的重中之重，是集团在北方布局的医疗器械产业基地。济南国际医学中心具有全国独一无二的医 教研产养服"六位一体"的综合发展业态，将为医疗器械企业提供高端研发服务、便捷审批渠道、丰富应 用场景、人才智力支持，全方位助力企业腾飞发展。 齐鲁晚报齐鲁壹点记者李培乐 近日，值第91届中国国际医疗器械博览会(CMEF)在上海召开之际，由济南国际医学（000516）中心管 委会主办、海凭国际.济南医疗器械产业园承办的济南国际医学中心医疗器械产业政策推介及项目招商 会成功举办，吸引了上百位医疗行业嘉宾到场共洽商机。 会上，济南国际医学中心管委会副主任徐强详细介绍了济南国际医学中心的产业发展情况，以及为医疗 器械产业提供的优惠政策，包括资金奖励、产品注册、创新研发、人才引进等方面的具体措施，旨在吸 引更多优质医疗器械企业入驻。医学中心愿与各方企业联手实现共建共享共赢，共同推动山东医疗器械 产业的快速发展。 推介会邀请了上海同济大学医学院副教授陈炳地、美国菲士公司中国区CEO姚志芹、欧姆龙医疗器械公 司销售总监杜聪等业内专家，分别就" ...

Group 1 - The banking industry is actively providing special loans for stock repurchase and increase to support the stable operation of the capital market, with several banks disclosing their progress and plans in this area [1][2] - Major state-owned banks are intensifying their efforts in stock repurchase and increase loan services, committing to support the financing needs of listed companies and their major shareholders [1][2] - Industrial and Commercial Bank of China has initiated a special action to support listed companies in stock repurchase and increase, addressing corporate funding needs of nearly 50 billion yuan [1] Group 2 - Agricultural Bank of China is focusing on providing special loans for stock repurchase and increase to quality listed companies, having reached cooperation intentions with several central state-owned enterprises and private listed companies [2] - China Bank has supported 73 listed companies' stock repurchase and increase plans, with a total loan intention amount of 25.36 billion yuan as of the end of March [2] - Construction Bank has established a special team for stock repurchase and increase, engaging with over 80 interested companies for loan services [2] Group 3 - As of the end of March, Industrial Bank has reached cooperation with 44 listed companies or major shareholders for stock repurchase and increase loans, with a loan ceiling exceeding 6.6 billion yuan, where over 80% are private enterprises and over 60% are technology companies [6] - As of April 9, Zhejiang Merchants Bank has reached cooperation intentions with nearly 60 listed companies and shareholders for stock repurchase and increase loans, with a planned repurchase amount exceeding 8 billion yuan and a credit fund scale exceeding 5 billion yuan [7] Group 4 - Other banks such as Postal Savings Bank, Huaxia Bank, and Everbright Bank have announced shareholder increase plans, signaling positive prospects for the future development of listed banks [8] - The stock repurchase and increase re-loan program was established in October last year as a new tool to encourage financial institutions to provide loans to eligible listed companies and major shareholders for stock repurchase and increase [8]

Core Viewpoint - The article highlights the increasing support from commercial banks for stock repurchase and increase loans to listed companies, which is expected to stabilize and promote the development of the capital market [1][11][12]. Group 1: Bank Support for Stock Repurchase and Increase Loans - As of April 9, over 400 A-share listed companies have received bank loan limits exceeding 871 billion yuan for stock repurchase and increase, indicating strong bank support [1][13]. - In March, 47 A-share listed companies applied for bank repurchase and increase loans totaling 113.9 billion yuan, a significant month-on-month increase of approximately 45% [2]. - By April 9, 12 A-share listed companies had received over 46 billion yuan in bank-supported repurchase and increase loans [2]. Group 2: Specific Bank Initiatives - Agricultural Bank has provided stock repurchase and increase loans to 53 listed companies across various sectors, with a total signed loan amount exceeding 150 billion yuan [3]. - China Citic Bank's Dalian branch successfully executed a stock increase loan of 45 million yuan for a private enterprise, marking a significant step in the Northeast region [4]. - Postal Savings Bank has actively engaged with companies to tailor financing solutions for stock repurchase and increase needs [3]. Group 3: Government and Regulatory Support - Various local state-owned assets departments and financial regulatory bodies have held meetings to discuss stock repurchase and increase efforts, emphasizing the importance of maintaining market stability [6][8]. - In Shandong province, 42 companies have announced stock repurchase and increase loan approvals, totaling 64 billion yuan [7]. Group 4: Future Outlook - The article suggests that the scale of repurchase and increase loans will continue to grow, with more companies expected to participate, thereby enhancing market confidence and attracting long-term investors [11][13].